EC Pulmonology and Respiratory Medicine

Commentary Volume 15 Issue 2 - 2026

Why does Severe Acute Pneumonia Remain a Stumbling Block for Modern Medicine?

Igor Klepikov*

MD, Professor, Retired, Renton, WA, USA

*Corresponding Author: Igor Klepikov, MD, Professor, Retired, Renton, WA, USA.
Received: January 27, 2026; Published: February 02, 2026



  1. GBD 2021 Lower Respiratory Infections and Antimicrobial Resistance Collaborators. “Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990-2021: a systematic analysis from the Global Burden of Disease Study 2021”. Lancet Infectious Diseases 24 (2024): 974-1002.
  2. A Putot., et al. “Comprehensive management of pneumonia in older patients”. European Journal of Internal Medicine 135 (2025): 14-24.
  3. Povoa P, et al. “How to approach a patient hospitalized for pneumonia who is not responding to treatment?” Intensive Care Medicine 5 (2025): 893-903.
  4. Podolsky SH. “The changing fate of pneumonia as a public health concern in 20th-century America and beyond”. American Journal of Public Health 12 (2005): 2144-2154.
  5. Oran DP and Topol EJ. “Prevalence of asymptomatic SARS-CoV-2 infection: a narrative review”. Annals of Internal Medicine 5 (2020): 362-367.
  6. Wu Z and McGoogan JM. “Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases from the Chinese Center for Disease Control and Prevention”. Journal of the American Medical Association 13 (2020): 1239-1242.
  7. Nuala Meyer. “Dysregulated host immune response is the driver of disease progression and severe patient outcomes”. Respiratory AMJ1 (2023): 26-35.
  8. Pratik Sinha. “Severe viral lower respiratory tract infections pose a significant burden on patients and healthcare systems”. Respiratory AMJ1 (2023): 26-35.
  9. Maricar Malinis., et al. “Community-acquired pneumonia: a US perspective on the guideline gap”. Journal of Antimicrobial Chemotherapy5 (2024): 959-961.
  10. Giamarellos-Bourboulis EJ., et al. “Clarithromycin for early anti-inflammatory responses in community-acquired pneumonia in Greece (ACCESS): a randomised, double-blind, placebo-controlled trial”. Lancet Respiratory Medicine 4 (2024): 294-304.
  11. Long ME., et al. “Pathogenesis of pneumonia and acute lung injury”. Clinical Science (London)10 (2022): 747-769.
  12. Khan MA., et al. “Pneumonia: Recent updates on diagnosis and treatment”. Microorganisms3 (2025): 522.
  13. Hellou M., et al. “Performance of BIOFIRE FILMARRAY pneumonia panel in suspected pneumonia: insights from a real-world study”. Microbiology Spectrum 7 (2025): e00571-25.
  14. WHO Solidarity Trial Consortium. “Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results. February 11, 2021”. New England Journal of Medicine 384 (2021): 497-511.
  15. R Isturiz., et al. “Expanded analysis of 20 pneumococcal serotypes associated with radiographically confirmed community-acquired pneumonia in hospitalized US adults”. Clinical Infectious Diseases7 (2021): 1216-1222.
  16. Olarte L., et al. “Higher-valent pneumococcal conjugate vaccines—perspective for 2026”. JAMA Internal Medicine 12 (2025): 1493-1494.
  17. Huttner BD., et al. “COVID-19: don't neglect antimicrobial stewardship principles!” Clinical Microbiology and Infection 7 (2020): 808-810.
  18. Beović B., et al. “Antibiotic use in patients with COVID-19: a 'snapshot' Infectious Diseases International Research Initiative (ID-IRI) survey”. Journal of Antimicrobial Chemotherapy 11 (2020): 3386-3390.
  19. Rawson TM., et al. “Bacterial and fungal coinfection in individuals with coronavirus: a rapid review to support covid-19 antimicrobial prescribing”. Clinical Infectious Diseases 9 (2020): 2459-2468.
  20. David C Fajgenbaum and Carl H June. “Cytokine Storm”. New England Journal of Medicine 23 (2020): 2255-2273.
  21. Lipman M., et al. “SARS-CoV-2 pandemic: clinical picture of COVID-19 and implications for research”. Thorax 8 (2020): 614-616.
  22. Arunachalam PS. “Immune responses to SARS-CoV-2 in the lung”. Thorax 10 (2021).
  23. D Clark Files., et al. “A pilot study to assess the circulating renin-angiotensin-system in covid-19 acute respiratory failure”. American Journal of Physiology-Lung Cellular and Molecular Physiology1 (2021).
  24. van de Veerdonk FL. “COVID-19 pneumonia and cytokine storm syndrome”. In: Cron, R.Q., Behrens, E.M. (eds) Cytokine Storm Syndrome. Advances in Experimental Medicine and Biology, vol 1448. Springer, Cham (2024).
  25. I Klepikov. “Myths, Legends and Real Facts About Acute Lung Inflammation”. Cambridge Scholars Publishing. ISBN: 1-0364-0293-2, ISBN13: 978-1-0364-0293-8 (2024): 338.
  26. Cajander Sara., et al. “Profiling the dysregulated immune response in sepsis: overcoming challenges to achieve the goal of precision medicine”. The Lancet Respiratory Medicine4 (2024): 305-322.
  27. Gross CP., et al. “Artificial intelligence and clinical care: JAMA Internal Medicine call for papers”. JAMA Internal Medicine 12 (2025): 1418-1420.
  28. Ziad Obermeyer. “Bedside to Bench - AI and the new science of medicine”. New England Journal of Medicine 393 (2025): 2287-2289.
  29. Phan HV., et al. “Integrating a host biomarker with a large language model for diagnosis of lower respiratory tract infection”. Nature Communications 1 (2025): 10882.

Igor Klepikov. “Why does Severe Acute Pneumonia Remain a Stumbling Block for Modern Medicine?”. EC Pulmonology and Respiratory Medicine 15.2 (2026): 01-06.

ECronicon Journal

Our Services

Quick Links

Information

Creative Commons LicenseOpen Access by ECronicon is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at www.ecronicon.net